New Hansa CEO Outlines Hopes And Plans For 2020 Lead Asset Launch
Søren Tulstrup says Hansa remains confident of achieving at least a conditional approval for lead asset IdeS, with potential renal transplant launch by early 2020.
You may also be interested in...
The Global AMR R&D Hub’s newly launched Dynamic Dashboard aims to be “a comprehensive knowledge center for AMR R&D and market reforms,” its head tells Scrip.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.
The EMA has recommended Sanofi’s anti-CD38 antibody Sarclisa as a combination-based third-line treatment for multiple myeloma, after US approval earlier in March.